Patient diagnosed with acromegaly and pituitary apoplexy after breast carcinoma treatment: challenges in diagnosis and management
Ignacio Jiménez Hernando , Laura González Fernández
Exploration of Endocrine and Metabolic Diseases ›› 2024, Vol. 1 ›› Issue (5) : 234 -43.
The clinical case presented describes a 44-year-old woman with a history of mucinous carcinoma in the right breast, who is diagnosed with a pituitary adenoma. Physical examination revealed signs of acromegaly, such as macroglossia and palmar hyperhidrosis. Hormonal tests were performed and showed elevated levels of insulin-like growth factor type 1 (IGF-1). The patient received GnRH analogues for breast cancer; and started medical treatment with somatostatin analogues for acromegaly, which provided improvement in symptoms. Pituitary bleeding was detected during hormone treatment, which caused the growth of the adenoma, causing it to contact the optic chiasm, although no symptoms of pituitary apoplexy were present. Transsphenoidal endoscopic surgery was performed to remove the adenoma, and the diagnosis of pituitary adenoma was confirmed by pathology. The importance of the evaluation of comorbidities in patients with acromegaly is discussed. Pituitary apoplexy as an uncommon complication of pituitary adenomas, which may be associated with the use of GnRH analogues, is addressed. Pre-surgical medical treatment in acromegaly is also discussed, highlighting the importance of a comprehensive assessment of prognostic factors and appropriate treatment selection to improve clinical outcomes. In conclusion, the importance of a multidisciplinary and personalized approach in the management of patients with GH-producing pituitary adenomas to improve quality of life and clinical outcomes is highlighted.
Acromegaly / pituitary apoplexy / GnRH analogues / somatostatin analogues / pituitary adenoma
| [1] |
Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, |
| [2] |
Fleseriu M, Langlois F, |
| [3] |
Danilowicz K, Sosa S. Acromegaly and Cancer: An Update. Arch Med Res. 2023; 54: 102914. |
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
Mercado M, Gonzalez B, Vargas G, Ramirez C, |
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
Sabbah N, Wolf P, Piedvache C, Trabado S, Verdelet T, Cornu C, |
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 2000; 6: 4789-96. |
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
Lundin P, |
| [42] |
|
| [43] |
|
| [44] |
Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab. 1998; 83: 3411-8. |
| [45] |
|
| [46] |
|
| [47] |
|
/
| 〈 |
|
〉 |